University Hospital of Zurich
Welcome,         Profile    Billing    Logout  
 27 Trials 
54 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ulrich, Silvia
NCT03537924: Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude

Active, not recruiting
4
100
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/22
12/22
NCT03539367: Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude

Active, not recruiting
4
100
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/22
12/22
NCT06498505: HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men

Recruiting
4
270
RoW
Acetazolamide, Placebo
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov, University Hospital Heidelberg, Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
High Altitude
12/25
12/25
NCT03540914: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.

Active, not recruiting
4
400
RoW
ACETAZOLAMIDE oral capsule, Placebo oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Altitude Hypoxia
12/24
12/24
NCT04915365: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude

Recruiting
3
100
RoW
Acetazolamide, Acetazolamide, oral capsule, Placebo, Placebo, oral capsule
University of Zurich, National Center of Cardiology and Internal Medicine, Kyrgyz Republic
Right Heart Function, Chronic Obstructive Pulmonary Disease, Altitude Sickness
12/22
12/23
ESRA, NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH

Recruiting
2
70
Europe
Riociguat Oral Tablet, MK-4836, ATC Code: C02KX05, Placebo
Heidelberg University, Merck Sharp & Dohme LLC
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
10/25
06/26
PEGASUS, NCT03051763: The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension

Recruiting
N/A
1000
Europe
University of Giessen, Universitätsklinikum Hamburg-Eppendorf, DRK Kliniken Berlin Köpenick, Berlin, Germany, University Hospital, Zürich, University Hospital Carl Gustav Carus
Pulmonary Hypertension, Pulmonary Arterial Hypertension
12/21
05/22
NCT05185895: Visa-versa! Breaking Instead of Pushing the Pedals-D

Completed
N/A
24
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Healthy (Controls)
12/22
04/23
NCT05186987: Visa-versa! Breaking Instead of Pushing the Pedals-A

Completed
N/A
33
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Pulmonary Hypertension
08/23
09/23
HEXASN, NCT04706546: Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Completed
N/A
24
Europe
Hemodynamic effect of exercise under Sildenafil, Hemodynamic effect of exercise
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXABM, NCT04715113: Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXASH, NCT04697862: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%) under Sildenafil, Normobaric hypoxia (FiO2 15%)
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXAS, NCT04704440: Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%), Normobaric hypoxia (FiO2 15%) under Sildenafil, Placebo-ambient air (FiO2 21%) under Sildenafil
University of Zurich
Hypertension, Pulmonary
05/23
05/23
HEXA, NCT04697875: Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension

Completed
N/A
24
Europe
Normobaric hypoxia (FiO2 15%), Placebo-ambient air (FiO2 21%)
University of Zurich
Hypertension, Pulmonary
05/23
05/23
PEX-NET, NCT03954574: Pulmonary Hemodynamics During Exercise - Research Network

Recruiting
N/A
1500
Europe, US, RoW
assessment of pulmonary hemodynamics during exercise by right heart catheterization
Medical University of Graz, European Respiratory Society
Pulmonary Circulation Diseases
12/29
12/29
NCT05204693: Visa-versa! Breaking Instead of Pushing the Pedals-C

Recruiting
N/A
16
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Left Heart Failure
12/23
07/24
NCT05185856: Visa-versa! Breaking Instead of Pushing the Pedals-B

Recruiting
N/A
16
Europe
15 minutes eccentric cycling, 15 minutes concentric (normal) cycling
University of Zurich
Chronic Obstructive Pulmonary Disease
07/24
12/24
NCT05996302: HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Relocation to sea level
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06084559: HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
Supplemental oxygen therapy, Sham Oxygen therapy, Placebo
University of Zurich
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06072417: HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

Active, not recruiting
N/A
24
Europe
Assessment without intervention at High altitude, Relocation to sea level for 2 days
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06003244: High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

Active, not recruiting
N/A
24
Europe
6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
12/23
12/23
NCT06385301: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

Not yet recruiting
N/A
14
Europe
6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)
University of Zurich
Lung Disease Chronic, Lung Diseases, Interstitial, Lung Diseases, Obstructive
05/25
11/25
NCT06384534: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)

Not yet recruiting
N/A
28
Europe
6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen
University of Zurich
Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
05/25
11/25
NCT06489704: High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

Not yet recruiting
N/A
24
RoW
Echocardiography
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489743: Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Not yet recruiting
N/A
24
RoW
6-minute walk test (6MWT)
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489756: Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Not yet recruiting
N/A
24
RoW
Echocardiography
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489691: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)

Not yet recruiting
N/A
24
RoW
6-minute walk test (6MWT)
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489717: High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)

Not yet recruiting
N/A
24
RoW
SDB assessment
University of Zurich
High Altitude Pulmonary Hypertension
12/24
12/24
NCT06489730: HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

Not yet recruiting
N/A
120
NA
University of Zurich, National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
High Altitude Pulmonary Hypertension, Sleep Apnea
12/24
12/24
ZHPHCohort, NCT02249806: Zürich Pulmonary Hypertension Outcome Assessment Cohort

Recruiting
N/A
100
Europe
PH target therapy according to physician
University of Zurich
Pulmonary Hypertension Outcome Assessment
09/24
09/24
NCT05610631: Pulmonary Hypertension Registry Switzerland

Recruiting
N/A
1000
Europe
University of Zurich, Actelion
Pulmonary Hypertension
12/27
12/27
Guckenberger, Matthias
DOSIS RCT, NCT02800551: Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases

Active, not recruiting
2
219
Europe
dose-intensified image-guided SBRT using simultaneous integrated boost, External 3-dimensional conformal radiotherapy (3D-CRT)
University of Zurich
Spinal Metastasis
01/23
07/24
SAKK 16/18, NCT04245514: Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
90
Europe
Durvalumab, Radiotherapy
Swiss Group for Clinical Cancer Research
Non-small Cell Lung Cancer, NSCLC
12/25
12/31
MASPAC, NCT05114213: MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

Recruiting
2
92
Europe
SBRT, oMRgRT, SOC chemotherapy
Ludwig-Maximilians - University of Munich, Heidelberg University, University of Zurich
Pancreatic Cancer
12/23
05/24
AUSTRAL, NCT06680050: Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Not yet recruiting
2
21
Europe
Durvalumab (MEDI4736), Ceralasertib, radiotherapy
Mario Negri Institute for Pharmacological Research
Non Small Cell Lung Cancer NSCLC
01/27
01/28
STEREO, NCT04908956 / 2020-004114-35: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC

Terminated
2
6
Europe, RoW
Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT)
ETOP IBCSG Partners Foundation, AstraZeneca
NSCLC Stage IV, EGFR Gene Mutation
10/23
02/24
CHESS, NCT03965468 / 2018-003011-22: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
SPRINT, NCT06462963: OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment

Not yet recruiting
N/A
302
NA
single-fraction SBRT, multiple-fraction SBRT
European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer, Oligometastatic Disease
11/28
11/28
HypoFocal SRT, NCT05746806: Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy

Recruiting
N/A
36
Europe
Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy, Androgen deprivation therapy
Insel Gruppe AG, University Hospital Bern, University of Bern, Debiopharm International SA, Werner und Hedy Berger-Janser - Stiftung
Recurrent Prostate Cancer
09/25
08/27
OligoRARE, NCT04498767: Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers

Recruiting
N/A
200
Europe
Stereotactic body radiotherapy, SBRT, Palliative RT
European Organisation for Research and Treatment of Cancer - EORTC, Anticancer Fund, Belgium, Rising Tide Foundation
Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma, Renal Cancer, Bladder Cancer, Upper Urinary Tract Carcinoma, Pancreatic Cancer, Hepatobiliary Cancer, Gastric Cancer, Small Bowel Cancer, Esophageal Cancer, Melanoma, Colon Cancer, Oligometastasis
08/28
02/30
Maisano, Francesco
EMCAMI, NCT06282042: Early Transcatheter Mitral Valve Repair After Myocardial Infarction

Not yet recruiting
4
250
Europe, RoW
Early transcatheter edge-to-edge mitral valve repair (TEER)., MitraClip, Optimal medical treatment
Fundación para la Investigación Biosanitaria del Principado de Asturias, Meditrial Europe Ltd.
Acute Mitral Regurgitation
06/27
06/28
OPTIMAV, NCT06667128: Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)

Not yet recruiting
N/A
160
Europe
Rapid Uptitration of Guideline-Directed Medical Therapy, Elecsys® NT-proBNP - Roche Diagnostics, Point-of-Care (PoC) Monitoring, Rapid Up-Titration GDMT Group with Hospital Monitoring
IRCCS Ospedale San Raffaele, Hoffmann-La Roche
Heart Failure, Valvulopathy, Aortic Stenosis, Aortic Regurgitation Disease, Mitral Regurgitation, Tricuspid Regurgitation, Brain Natriuretic Peptide, Mitraclip, TAVI(Transcatheter Aortic Valve Implantation)
02/26
02/26
NCT05927441: DragonFly EU Pivotal Study

Not yet recruiting
N/A
168
NA
DragonFly Transcatheter Mitral Valve Repair System, Transcatheter Mitral Valve repair (TMVr)
Hangzhou Valgen Medtech Co., Ltd
Mitral Valve Insufficiency
05/25
05/29
VANTAGE, NCT04788888: Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

Recruiting
N/A
590
Europe, RoW
Navitor Transcatheter Aortic Valve and FlexNav Delivery System
Abbott Medical Devices
Symptomatic Severe Aortic Stenosis
06/25
02/36
VISTA, NCT06008080: Post-Market Clinical Follow Up Study with Navitor Valve

Recruiting
N/A
1000
Europe, Japan
Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System
Abbott Medical Devices
Aortic Stenosis
01/26
12/30
APOLLO-EU, NCT05496998: Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - Trial

Recruiting
N/A
400
Europe
Medtronic Intrepid™ TMVR TF System
Medtronic Cardiovascular
Mitral Regurgitation
08/29
12/38
Kulcsar, Zsolt
TECNO, NCT05499832: Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

Recruiting
3
156
Europe
Tenecteplase
Insel Gruppe AG, University Hospital Bern
Ischemic Stroke
07/25
10/25
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25
DISTAL, NCT05029414: EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

Active, not recruiting
N/A
543
Europe, RoW
Endovascular Therapy
University Hospital, Basel, Switzerland, Swiss National Fund for Scientific Research, Stryker Neurovascular, Penumbra Inc., Medtronic, Phenox GmbH, Rapid Medical, Gottfried und Julia Bangerter-Rhyner-Stiftung
Acute Ischemic Stroke
10/24
06/25
Achermann, Yvonne
PHOMIC-III, NCT05676801: Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study

Recruiting
1
20
Europe
Photodynamic Therapy
University of Zurich
Prosthesis and Implants, Surgical Site Infection, Prosthetic Joint Infection, Postoperative Wound Infection Deep Incisional Surgical Site
09/23
12/23
Rose, Elizabeth
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25
Schiebler, Sarah
NCT05168124: Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis

Recruiting
N/A
90
Europe
Acceptance Commitment Therapy for chronic fatigue, Micro breaks in everyday life for chronic fatigue
Sarah Schiebler, University of Zurich
Fatigue Syndrome, Chronic
12/25
07/26
Deuel, Jeremy
REDEFINE, NCT06537726: Breath Analysis for the Detection of Invasive Fungal Infections

Recruiting
N/A
130
Europe
Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS), Blood sampling (serologic biomarkers, PCR), Sputum analysis, Low-dose CT
University of Zurich
Leukemia, Leukemia, Myeloid, Leukemia, Lymphoblastic, Neutropenia, Chemotherapy-induced Neutropenia, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis
08/26
02/27

Download Options